‘Two Weeks, To Flatten The Curve’
On a weekly closing basis (as we’ll see below), it’s obvious.
Upward (net) progress in biotech SPBIO, has come to a standstill.
While the media continues to foment the lie that somehow interest rates have reached their limit, or ‘Da Fed’, is going to do this or that, behind the scenes the plan … set out years ago, continues to unfold.
Before we get to the charts, let’s not forget what’s happening ‘out there‘. The number of idiots seems to be increasing without bound.
As Goethe said way back in 1826, ‘There is nothing more frightful than ignorance in action’. He was being polite with the ‘ignorance’ part.
Now, on to the charts.
The un-marked, chart of biotech SPBIO, is below.
The second chart zooms-in, showing the percentage changes on a closing basis.
Biotech SPBIO, Weekly
Zoom in, showing net progress.
One would think, since biotech has dropped so significantly, there’s no more (downside) left.
Certainly, anything can happen.
However, the premise is, the overall collapse is still in the early stages.
We have not (yet) had a 50% – 90%, drop in the S&P.
In addition, pension funds are likely to go broke.
Next up, the inverted chart of SPBIO, to mimic the action seen in leveraged inverse, LABD.
Then after that, is the same chart marked with a potential forecast of where price action may be heading (not advice, not a recommendation).
Now, the markup showing potential action should biotech continue its decline.
Zooming in on the last few weeks of action.
The fact price action has bounced from this area of the chart, tells us the trading range is valid; the blue line is being recognized by the market.
Now as shown, we’ve come to a halt.
So, what happens next?
As SPBIO ground its way higher (LABD lower) over the past week, the short position, LABD-22-02, was reduced further but not eliminated (not advice, not a recommendation).
Since there’s no more net progress upward and we’re still in an overall downtrend, expectations are for biotech to either stall, or reverse, continuing its trend lower.
As stated previously in this post, the market’s prior congestion was ‘complex’.
So, we’re expecting ‘simple’ this time around; all of which lends support to more downside.
Charts by StockCharts
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The Danger Point®, trade mark: No. 6,505,279